JP2018504894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504894A5 JP2018504894A5 JP2017532639A JP2017532639A JP2018504894A5 JP 2018504894 A5 JP2018504894 A5 JP 2018504894A5 JP 2017532639 A JP2017532639 A JP 2017532639A JP 2017532639 A JP2017532639 A JP 2017532639A JP 2018504894 A5 JP2018504894 A5 JP 2018504894A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- antibody
- nucleic acid
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 108700012439 CA9 Proteins 0.000 claims description 4
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 4
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims description 4
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 4
- 241000710831 Flavivirus Species 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 241000315672 SARS coronavirus Species 0.000 claims description 4
- 102100035721 Syndecan-1 Human genes 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- -1 ICOS Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022011441A JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
| JP2024147204A JP2024163140A (ja) | 2014-12-19 | 2024-08-29 | キメラ抗原受容体およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094625P | 2014-12-19 | 2014-12-19 | |
| US62/094,625 | 2014-12-19 | ||
| US201562252083P | 2015-11-06 | 2015-11-06 | |
| US62/252,083 | 2015-11-06 | ||
| PCT/US2015/067225 WO2016100985A2 (en) | 2014-12-19 | 2015-12-21 | Chimeric antigen receptors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011441A Division JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018504894A JP2018504894A (ja) | 2018-02-22 |
| JP2018504894A5 true JP2018504894A5 (enExample) | 2019-02-07 |
Family
ID=55229842
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532639A Pending JP2018504894A (ja) | 2014-12-19 | 2015-12-21 | キメラ抗原受容体およびその使用方法 |
| JP2022011441A Active JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
| JP2024147204A Pending JP2024163140A (ja) | 2014-12-19 | 2024-08-29 | キメラ抗原受容体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011441A Active JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
| JP2024147204A Pending JP2024163140A (ja) | 2014-12-19 | 2024-08-29 | キメラ抗原受容体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170362297A1 (enExample) |
| EP (1) | EP3233900A2 (enExample) |
| JP (3) | JP2018504894A (enExample) |
| KR (1) | KR20170090506A (enExample) |
| CN (1) | CN108064252A (enExample) |
| AU (4) | AU2015364245B2 (enExample) |
| BR (1) | BR112017013176A2 (enExample) |
| CA (1) | CA2968412A1 (enExample) |
| IL (3) | IL320860A (enExample) |
| RU (1) | RU2017125531A (enExample) |
| WO (1) | WO2016100985A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6461800B2 (ja) * | 2012-10-04 | 2019-01-30 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法 |
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| KR20160145813A (ko) * | 2014-04-25 | 2016-12-20 | 다나-파버 캔서 인스티튜트 인크. | 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법 |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| SMT202100116T1 (it) | 2014-05-28 | 2021-05-07 | Agenus Inc | Anticorpi anti-gitr e metodi di utilizzo degli stessi |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| KR20180111870A (ko) | 2016-02-25 | 2018-10-11 | 셀 메디카 스위처란트 아게 | Pd-l1에 대한 결합 성분 |
| EP3432924A1 (en) * | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| IL321335A (en) | 2016-06-29 | 2025-08-01 | Checkpoint Therapeutics Inc | PD-L1-specific antibodies and methods of using them |
| SG11201900138TA (en) | 2016-07-07 | 2019-02-27 | Iovance Biotherapeutics Inc | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
| US11077178B2 (en) | 2016-09-21 | 2021-08-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use |
| JP6887492B6 (ja) * | 2016-10-04 | 2021-07-14 | プレシジョン バイオサイエンシズ，インク． | 遺伝子改変細胞で使用するための共刺激ドメイン |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| WO2018089829A1 (en) | 2016-11-10 | 2018-05-17 | Fortis Therapeutics, Inc. | Cd46-specific effector cells and uses thereof |
| CN108148862B (zh) * | 2016-12-05 | 2019-03-08 | 上海优卡迪生物医药科技有限公司 | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 |
| SG11201908492PA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| MY201573A (en) | 2017-05-12 | 2024-03-02 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN107337736B (zh) * | 2017-06-06 | 2019-07-26 | 上海优卡迪生物医药科技有限公司 | Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用 |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| WO2019178356A1 (en) * | 2018-03-14 | 2019-09-19 | Dana-Farber Cancer Institute, Inc. | Engineered cells, t cell immune modulating antibodies and methods for using the same |
| KR20200138741A (ko) | 2018-04-02 | 2020-12-10 | 내셔널 유니버시티 오브 싱가포르 | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 |
| JP2021521778A (ja) * | 2018-04-16 | 2021-08-30 | メモリアル スローン ケタリング キャンサー センター | Ｔ細胞枯渇、およびそれに関連する方法および組成物 |
| JP7542441B2 (ja) | 2018-05-11 | 2024-08-30 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 癌を治療するための方法及び組成物 |
| JP7447388B2 (ja) * | 2018-07-13 | 2024-03-12 | ナンジン レジェンド バイオテック カンパニー，リミテッド | 感染性疾患の治療のための共受容体システム |
| CN112930199B (zh) * | 2018-07-24 | 2024-08-13 | 恺兴生命科技(上海)有限公司 | 免疫效应细胞治疗肿瘤的方法 |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| EP3856775B9 (en) | 2018-09-27 | 2025-01-22 | Autolus Limited | Chimeric antigen receptor |
| AU2019385873A1 (en) * | 2018-11-26 | 2021-06-03 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| US11104732B2 (en) * | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
| JP2022529380A (ja) * | 2019-04-26 | 2022-06-21 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | キメラ抗原受容体構築物およびｃａｒ－ｔ細胞におけるそれらの使用 |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| SG11202111130SA (en) | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
| EP3983447A4 (en) | 2019-06-14 | 2023-06-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against muc1 and methods of use thereof |
| CA3146987A1 (en) * | 2019-07-17 | 2021-01-21 | National University Of Singapore | Functional binders synthesized and secreted by immune cells |
| JP2022541320A (ja) * | 2019-07-24 | 2022-09-22 | エウレカ セラピューティクス インコーポレイテッド | キメラ抗原受容体ｔ細胞及びその使用 |
| JP2023504271A (ja) * | 2019-12-02 | 2023-02-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｐｄ－ｌ１に対する抗体およびその使用方法 |
| EP4092053A4 (en) * | 2020-01-19 | 2024-01-17 | Chineo Medical Technology Co., Ltd. | ENHANCED RECEPTOR TO IMPROVE IMMUNE CELL FUNCTION |
| EP4148065A4 (en) * | 2020-05-08 | 2024-05-29 | SMT Bio Co., Ltd. | Chimeric antigen receptor for treatment of cancer |
| KR20230066149A (ko) | 2020-08-07 | 2023-05-12 | 포티스 테라퓨틱스, 인크. | Cd46을 표적화하는 면역접합체 및 이의 사용 방법 |
| WO2022173950A1 (en) * | 2021-02-11 | 2022-08-18 | The Trustees Of The University Of Pennsylvania | Ccr4-targeting chimeric antigen receptor cell therapy |
| KR20220136876A (ko) | 2021-04-01 | 2022-10-11 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| EP4164687A4 (en) * | 2021-04-12 | 2024-08-14 | Academia Sinica | IMPROVED CORONAVIRUS VACCINE |
| KR20220144000A (ko) | 2021-04-16 | 2022-10-26 | 주식회사 이뮤노로지컬디자이닝랩 | Programmed death-ligand 1(PD-L1)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
| US20240262917A1 (en) | 2021-05-06 | 2024-08-08 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
| KR20230089462A (ko) | 2021-12-13 | 2023-06-20 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR20230089464A (ko) | 2021-12-13 | 2023-06-20 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| CA3245511A1 (en) * | 2022-03-08 | 2025-06-13 | Vaxcell Bio Co Ltd | PD-L1 SPECIFIC CHIMERIC ANTIGENIC RECEPTOR AND IMMUNE CELL CONTAINING IT |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7750123B2 (en) | 2003-11-25 | 2010-07-06 | Dana Farber Cancer Institute, Inc. | Antibodies against SARS-CoV and methods of use thereof |
| EP1871807B1 (en) | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
| EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| RU2010127156A (ru) | 2007-12-06 | 2012-01-20 | Дана-Фарбер Кэнсер Инститьют, Инк. (Us) | Антитела против вируса гриппа и их применение |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| AU2011261396B2 (en) | 2010-06-02 | 2015-11-05 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013154760A1 (en) * | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| HK1207655A1 (en) | 2012-05-04 | 2016-02-05 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| CN104583230A (zh) * | 2012-07-13 | 2015-04-29 | 宾夕法尼亚大学董事会 | 通过共同引入双特异性抗体增强car t细胞的活性 |
| JP6461800B2 (ja) * | 2012-10-04 | 2019-01-30 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法 |
| KR20210108497A (ko) * | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| EP4292657A3 (en) | 2013-03-15 | 2024-03-20 | Dana Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| WO2015143194A2 (en) | 2014-03-19 | 2015-09-24 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| KR20160145813A (ko) | 2014-04-25 | 2016-12-20 | 다나-파버 캔서 인스티튜트 인크. | 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법 |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| EP3699196A1 (en) | 2014-10-06 | 2020-08-26 | Dana Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| BR112017013177A2 (pt) * | 2014-12-19 | 2018-05-15 | Dana Farber Cancer Inst Inc | receptores de antígeno quiméricos de anidrase carbônica ix e métodos de uso dos mesmos |
| CA3002674A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
-
2015
- 2015-12-21 KR KR1020177020045A patent/KR20170090506A/ko active Pending
- 2015-12-21 US US15/537,779 patent/US20170362297A1/en not_active Abandoned
- 2015-12-21 IL IL320860A patent/IL320860A/en unknown
- 2015-12-21 CA CA2968412A patent/CA2968412A1/en active Pending
- 2015-12-21 IL IL252295A patent/IL252295B2/en unknown
- 2015-12-21 CN CN201580069023.0A patent/CN108064252A/zh active Pending
- 2015-12-21 JP JP2017532639A patent/JP2018504894A/ja active Pending
- 2015-12-21 WO PCT/US2015/067225 patent/WO2016100985A2/en not_active Ceased
- 2015-12-21 IL IL302660A patent/IL302660B2/en unknown
- 2015-12-21 BR BR112017013176-5A patent/BR112017013176A2/en not_active Application Discontinuation
- 2015-12-21 AU AU2015364245A patent/AU2015364245B2/en active Active
- 2015-12-21 RU RU2017125531A patent/RU2017125531A/ru not_active Application Discontinuation
- 2015-12-21 EP EP15828615.3A patent/EP3233900A2/en active Pending
-
2020
- 2020-06-30 AU AU2020204373A patent/AU2020204373B2/en active Active
- 2020-08-06 US US16/986,913 patent/US12195514B2/en active Active
-
2022
- 2022-01-17 AU AU2022200257A patent/AU2022200257B2/en active Active
- 2022-01-28 JP JP2022011441A patent/JP7548950B2/ja active Active
-
2024
- 2024-01-31 AU AU2024200592A patent/AU2024200592A1/en active Pending
- 2024-08-29 JP JP2024147204A patent/JP2024163140A/ja active Pending
- 2024-12-05 US US18/970,194 patent/US20250243259A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504894A5 (enExample) | ||
| RU2017125531A (ru) | Химерные антигенные рецепторы и способы их применения | |
| HRP20240357T1 (hr) | Stanica | |
| WO2019090003A9 (en) | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) | |
| FI3896091T3 (fi) | BCMA:han kohdentuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2020114264A5 (enExample) | ||
| JP2018500337A5 (enExample) | ||
| HRP20191839T1 (hr) | Car ekspresijski vektor i t stanice koje eksprimiraju car | |
| JP2019527557A5 (enExample) | ||
| JP2016508518A5 (enExample) | ||
| JP2018534245A5 (enExample) | ||
| BR112018008442A2 (pt) | receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados | |
| MX2014010183A (es) | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. | |
| HK1252235A1 (zh) | 表达γ-δT细胞受体(TCR)和嵌合抗原受体(CAR)的T细胞 | |
| WO2017130223A3 (en) | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof | |
| JP2017529851A5 (enExample) | ||
| WO2017147383A8 (en) | Modified cells for immunotherapy | |
| EP4477748A3 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| PH12016502010A1 (en) | Drug related transgene expression | |
| WO2016109410A3 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| JP2017513478A5 (enExample) | ||
| FI4219687T3 (fi) | Menetelmiä immuunisolupopulaatioiden eristämiseksi, viljelemiseksi ja geneettiseksi muokkaamiseksi adoptiivista terapiaa varten | |
| RU2018111462A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| JP2014534207A5 (enExample) | ||
| JP2018514576A5 (enExample) |